The boardroom and the trading floor are telling two very different stories about Gerresheimer. While Barclays warns the shares are heading for 19 euros, supervisory board member Klaus Röhrig has been buying in bulk — spending nearly 14 million euros to accumulate stock through two investment vehicles.
The transactions, disclosed in official filings, show Röhrig’s AOC Gecko S.à r.l. and the Active Ownership Fund together snapped up roughly 530,000 shares at 24.04 euros apiece in late April, in off-exchange deals. Days later, on May 6, AOC Gecko added further shares via Xetra, this time paying an average of 25.85 euros — a noticeably higher entry price.
The market rewarded the show of confidence. Gerresheimer shares jumped more than 3% on Friday to 27.66 euros, extending a one-month gain of around 55%. Yet the stock remains more than 54% lower than a year ago, a reminder of the deep hole from which it is climbing.
A Rally Built on Borrowed Time
That recovery has been nothing short of dramatic. From a February low of 15.57 euros, the stock has surged more than 70% in three months. But the catalyst has little to do with operations. Gerresheimer secured a standstill agreement on 870 million euros of Schuldschein loans through September 2026, with lenders temporarily waiving leverage covenants. The move staved off an immediate liquidity crunch — but it did nothing to resolve the core problem.
The company has yet to publish its audited 2025 annual report. A second external audit firm is now examining business transactions from 2024 and 2025, and management is targeting a June 2026 release. Until the audit opinion is delivered, institutional investors remain locked out — a constraint that contributed to the stock’s expulsion from the SDAX.
Alongside the annual report, Gerresheimer plans to release its first-quarter 2026 results. The annual general meeting has been postponed with no new date set, and the half-year report is scheduled for July 14.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Impairments and Plant Closures Weigh on the Balance Sheet
For the 2025 financial year, the company expects non-cash impairment charges of 220 million to 240 million euros, linked to projects at Sensile Medical AG and assets at the Chicago Heights glass plant. That facility will close on September 30, with 172 employees losing their jobs as production shifts to Italy and India.
Despite these headwinds, management has reaffirmed its full-year guidance: revenue of 2.3 billion to 2.4 billion euros, an adjusted EBITDA margin of 18% to 19%, and moderately positive free cash flow. The forecast is conditional on a favourable outcome from BaFin’s review.
The Technical Picture Hinges on a Single Line
Chart watchers have their eyes on a specific threshold. At 27.66 euros, Gerresheimer is testing the 200-day moving average, which sits at 27.83 euros. A clean break above that level would formally end the medium-term downtrend — but the rally’s sustainability depends on what happens in June.
Barclays, for its part, remains unconvinced. The bank recently downgraded the stock to “Underweight” with a 19-euro price target, arguing that significant downside remains from current levels.
The June audit opinion will be the first real test of trust. If the company delivers an unqualified audit, it removes the biggest barrier to institutional buying. If not, the rally built on a creditor reprieve and insider buying could unwind just as quickly as it began.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from May 8 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 8.
Gerresheimer: Buy or sell? Read more here...
